Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/18/2025 | $75.00 | Outperform | Wolfe Research |
| 10/7/2025 | $125.00 | Buy | Goldman |
| 8/20/2025 | $123.00 | Overweight | Wells Fargo |
| 6/23/2025 | $110.00 | Buy | TD Cowen |
| 3/5/2025 | $74.00 | Buy | Stifel |
| 12/2/2024 | $74.00 | Buy | Stifel |
| 12/2/2024 | $72.00 | Outperform | Robert W. Baird |
| 9/3/2024 | $70.00 | Buy | H.C. Wainwright |
4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
Wolfe Research initiated coverage of Soleno Therapeutics with a rating of Outperform and set a new price target of $75.00
Goldman initiated coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $125.00
Wells Fargo initiated coverage of Soleno Therapeutics with a rating of Overweight and set a new price target of $123.00
REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today regrets to announce the passing of William G. "Bill" Harris, who served as a valued member of Soleno's Board of Directors since June 2014. Mr. Harris also served as Chairman of the Audit Committee. "I have known Bill for many years, and always viewed him as a person of integrity, who exhibited pragmatism and a genuine desire to help others," said Dr. Anish Bhatnagar, Chief Executive Officer and Chairman of the Board of Soleno Therapeutics. "His guidance and insights, culled from decades
REDWOOD CITY, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37th Healthcare Conference on Thursday, December 4, 2025, at 9:00 AM Eastern Time. A live audio webcast and replay of the presentation will be available in the Investors section on the Company's website at www.soleno.life. About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare disease
REDWOOD CITY, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that its Board of Directors has authorized a share repurchase and that it has entered into an Accelerated Share Repurchase Agreement ("ASR") with Jefferies LLC ("Jefferies") to repurchase $100 million of Soleno's common stock. "These actions demonstrate our confidence in our commercial launch and the compelling opportunity for VYKAT XR to become a foundational therapy for patients with hyperphagia associated with Prader Willi syndrome," said Dr. Anish Bhatnagar, Chief Execut
SCHEDULE 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)
8-K - SOLENO THERAPEUTICS INC (0001484565) (Filer)
10-Q - SOLENO THERAPEUTICS INC (0001484565) (Filer)
4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
3 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
REDWOOD CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of biopharmaceutical finance veteran Mark W. Hahn as an independent director to its Board of Directors and a member of its Audit Committee. Mr. Hahn brings to Soleno's Board nearly 30 years of CFO-level experience and has played a key role in numerous successful product launches, financings, and M&A transactions within the life sciences sector. With the addition of Mr. Hahn, the Soleno Board increases to seven seats. "I am very pleased to welcome Mark to the
REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. "Inclusion in the Russell indexes is a significant milestone and reflects the meaningful progress Soleno has made in advancing our lead candidate DCCR (diazoxide choline) extended-release ta
REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointments of Meredith Manning, M.B.A as Chief Commercial Officer, Dairine Dempsey, Ph.D. as Vice President, Europe and Lauren Budesheim, M.S. as Vice President of Human Resources. The Company also announced the appointment of key advisors with Shamim Ruff, M.S. joining as Chair of the Development Advisory Board and James (Jim) Geraghty, J.D., M.S. as a Board Advisor. "As we move into the next phase of Soleno's growth, we are delighted to welcome seasone
REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the third quarter ended September 30, 2025 and provided an update on the U.S. launch of VYKATTM XR. Third Quarter 2025 and Recent Corporate Highlights Revenue, net, from the sale of VYKAT XR for the three months ended September 30, 2025 was $66.0 million and the Company achieved profitability with positive net income of $26.0 million for the third quarter.From approval on March 26, 2025 through September 30, 2025, Soleno reports: 1,043 patient start form
REDWOOD CITY, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its third quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Tuesday, November 4, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Tuesday, November 4, 2025Time:4:30 PM Eastern TimeUnited States:1-800-717-1738International:1-646-307-1865Conf
REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 and Recent Corporate Highlights Announced launch of VYKAT XR and commencement of patient treatments on April 14, 2025.From approval on March 26, 2025 through June 30, 2025, Soleno reports: 646 patient start forms received295 unique prescribers of VYKAT XROver 100 million lives covered Announced submission and validation of Market
SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)
SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)
SC 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)